Clinical presentation and management of acquired thrombotic thrombocytopenic purpura: A case series of 55 patients

医学 ADAMTS13号 血栓性血小板减少性紫癜 微血管病性溶血性贫血 内科学 胃肠病学 美罗华 血浆置换术 血小板 免疫学 抗体 淋巴瘤
作者
Ruixue Sun,Jun Xu,Huadong Zhu,Xue‐Zhong Yu,Jing Yang
出处
期刊:Therapeutic Apheresis and Dialysis [Wiley]
卷期号:25 (1): 118-123 被引量:8
标识
DOI:10.1111/1744-9987.13502
摘要

The aim of this study was to explore the clinical characteristics and treatment of acquired thrombotic thrombocytopenic purpura (TTP). The clinical manifestations, laboratory findings, differential diagnoses, therapeutic methods, and prognosis of 55 patients with acquired TTP were retrospectively analyzed. Among the 55 TTP patients, 17 were males and 38 were females, with a mean age of 40 ± 15 years. Twenty-one patients had the Triad syndrome, which included neurological syndromes, microangiopathic hemolytic anemia, and thrombocytopenia. Twenty-three patients had the Quinary syndrome, which included fever, microangiopathic hemolytic anemia, thrombocytopenia, renal insufficiency, and neurological symptoms. Twenty-eight patients received the measurement for a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity and 23 patients had <10% of the normal range. ADAMTS13 inhibitor was tested in 20 patients and was positive in 18 patients. Both ADAMTS13 activity and ADAMTS13 inhibitor were examined in 20 patients and 90% of the patients showed double positive results. The treatment methods included plasma exchange, glucocorticoids, rituximab, immunosuppressants, and intravenous immunoglobulin. Thirty-three patients survived, and 22 patients died. Plasma exchange improved the remission rate from 16.7% to 65.3% (P = .022). The combined immunosuppressive therapy based on plasma exchange and glucocorticoids raised the remission rate from 43.8% to 75.8%. Most of acquired TTP patients had the Triad syndrome or the Quinary syndrome. A high proportion of TTP patients had ADAMTS13 activity reduction and ADAMTS13 inhibitor positivity. Plasma exchange and immunosuppressive therapy may improve the prognosis of this disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
冬瓜鑫发布了新的文献求助10
刚刚
秋风的应助被qqqxxx采纳,获得20
1秒前
1秒前
zzhou发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
moaner完成签到,获得积分10
2秒前
2秒前
斯文败类的应助被Wink213采纳,获得10
2秒前
石愚志发布了新的文献求助10
2秒前
高大鸣凤完成签到,获得积分10
3秒前
木子完成签到,获得积分10
3秒前
小马甲的应助被飘逸迎丝采纳,获得10
3秒前
飞蚁完成签到 ,获得积分10
3秒前
4秒前
李旭珍最爱的香香宝贝完成签到,获得积分10
4秒前
顺颂时祺发布了新的文献求助10
4秒前
mujinhuanxin完成签到,获得积分10
4秒前
张yusong完成签到,获得积分20
4秒前
4秒前
5秒前
一颗石榴发布了新的文献求助10
5秒前
5秒前
完美世界的应助被顺利毕业采纳,获得10
5秒前
不七完成签到 ,获得积分10
5秒前
千空发布了新的文献求助10
6秒前
7秒前
石愚志发布了新的文献求助10
7秒前
石愚志发布了新的文献求助10
7秒前
石愚志发布了新的文献求助10
7秒前
石愚志发布了新的文献求助10
7秒前
郑云心关注了科研通微信公众号
7秒前
Lucas的应助被QiongBai520采纳,获得10
7秒前
8秒前
钟梓袄发布了新的文献求助10
8秒前
CHONGMING完成签到,获得积分10
9秒前
han发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124